2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-Based Immunotherapies

2seventy bio, Inc. and JW Therapeutics announced a strategic alliance to establish a translational and clinical cell therapy development platform designed to more rapidly explore T cell-based immunotherapy therapy products in the Chinese mainland, Hong Kong, and Macao.